ED
VKTX icon

Exane Derivatives’s Viking Therapeutics VKTX Stock Holding History

Exane Derivatives’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-27,776
Closed -$83.3K – 985
2022
Q1 		$83.3K Buy
+27,776
New +$99.6K 0.02% 492
2021
Q4 		– Sell
-30,145
Closed -$189K – 1036
2021
Q3 		$189K Buy
30,145
+6,172
+26% +$38.1K 0.05% 403
2021
Q2 		$141K Sell
23,973
-21,109
-47% -$125K 0.03% 495
2021
Q1 		$285K Sell
45,082
-6,202
-12% -$43.6K 0.08% 231
2020
Q4 		$289K Buy
51,284
+6,407
+14% +$38.8K 0.08% 252
2020
Q3 		$261K Buy
44,877
+1,004
+2% +$6.91K 0.08% 187
2020
Q2 		$316K Sell
43,873
-9,301
-17% -$61.8K 0.08% 187
2020
Q1 		$249K Buy
+53,174
New +$327K 0.07% 176

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Exane Derivatives's VKTX Position: Q2 2022 in Review

Exane Derivatives sold out of Viking Therapeutics (VKTX) in Q2 2022, closing a stake of 27,776 shares — an estimated $83.3K sold.

Exane Derivatives first reported a position in VKTX in Q1 2020 and held it in 8 quarters. The position peaked at $316K in Q2 2020. 114 funds tracked by Wall St. Rank hold VKTX as of Q2 2022.

  • Exane Derivatives reported no remaining Viking Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Exane Derivatives sold 27,776 Viking Therapeutics shares in Q2 2022, an estimated $83.3K.
  • Exane Derivatives first reported a position in Viking Therapeutics in Q1 2020 and held it in 8 quarters.
  • Exane Derivatives's Viking Therapeutics position peaked at $316K in Q2 2020.
  • 114 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.